Greenyn Biotechnology Co., Ltd
Greenyn Biotechnology Co., Ltd, a dietary supplement company, develops, manufactures, and sells health products in Taiwan and internationally. The company offers proprietary ingredients, such as Insumate, a bitter melon extract; Antromax, an antrodia cinnamomea; and Zymologist 101 Phyto fermented drink. It also provides functional formulas for youth and beauty series, digestive health series, bra… Read more
Market Cap & Net Worth: Greenyn Biotechnology Co., Ltd (6846)
Greenyn Biotechnology Co., Ltd (TWO:6846) has a market capitalization of $20.77K (NT$687.29K) as of March 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #43763 globally and #1944 in its home market, demonstrating a -1.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Greenyn Biotechnology Co., Ltd's stock price NT$71.60 by its total outstanding shares 9599 (9.60K).
Greenyn Biotechnology Co., Ltd Market Cap History: 2025 to 2026
Greenyn Biotechnology Co., Ltd's market capitalization history from 2025 to 2026. Data shows growth from $21.32K to $20.77K (0.00% CAGR).
Greenyn Biotechnology Co., Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Greenyn Biotechnology Co., Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6846 by Market Capitalization
Companies near Greenyn Biotechnology Co., Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Greenyn Biotechnology Co., Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Greenyn Biotechnology Co., Ltd Historical Marketcap From 2025 to 2026
Between 2025 and today, Greenyn Biotechnology Co., Ltd's market cap moved from $21.32K to $ 20.77K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$20.77K | -2.59% |
| 2025 | NT$21.32K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Greenyn Biotechnology Co., Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.77K USD |
| MoneyControl | $20.77K USD |
| MarketWatch | $20.77K USD |
| marketcap.company | $20.77K USD |
| Reuters | $20.77K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.